FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
obligations may continue. See Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

OMB APPROVAL 3235-0287 Estimated average burden

0.5

hours per response:

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* PARVEN ALVIN S					AL	2. Issuer Name and Ticker or Trading Symbol ALEXION PHARMACEUTICALS INC [ALXN]							Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title Other (specify)				
(Last) (First) (Middle) C/O ALEXION PHARMACEUTICALS, INC 100 COLLEGE STREET				01/0	te of Earliest Trans 5/2017					below)		belov	<i>)</i>)``				
(Street) NEW HAVEN CT 06510							4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting										
(City)	(S	state)	((Zip)									Person				
			Tab	le I - N	on-Deri	vative	Securities Ac	quire	d, Di	sposed of	, or Be	neficiall	y Owned				
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)			Acquired (A) or (D) (Instr. 3, 4 and 5)		- Reported	es ally Following d	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
								Code	v	Amount	(A) or (D)	Price	Transact (Instr. 3				
Common	Stock, par	value	\$.0001 per	share	01/05/	2017		M		7,932(1)	A	\$26.64	. 14,	,305	D		
Common	Stock, par	value	\$.0001 per	share	01/05/	2017		M		5,572(1)	A	\$49.43	19,	,877	D		
Common	Stock, par	value	\$.0001 per	share	01/05/	2017		M		3,237(1)	A	\$85.75	23,	,114	D		
Common	Stock, par	value	\$.0001 per	share	01/05/	2017		M		3,425(1)	A	\$96.35	26,	,539	D		
Common	Stock, par	value	\$.0001 per	share	01/05/	2017		S		185(1)	D	\$133.95	(2) 26,	,354	D		
Common	Stock, par	value	\$.0001 per	share	01/05/	2017		S		369(1)	D	\$135.70	3) 25,	,985	D		
Common	Stock, par	value	\$.0001 per	share	01/05/	2017		S		7,375(1)	D	\$137.56	(4) 18,	,610	D		
Common	Stock, par	value	\$.0001 per	share	01/05/	2017		S		5,176(1)	D	\$138.6 ⁽⁾	5) 13,	,434	D		
Common	Stock, par	value	\$.0001 per	share	01/05/	2017		S		5,350(1)	D	\$139.49	(6) 8,	084	D		
Common	Stock, par	value	\$.0001 per	share	01/05/	2017		S		1,433(1)	D	\$140.59	(7) 6,	651	D		
Common	Stock, par	value	\$.0001 per	share	01/05/	2017		S		278(1)	D	\$141.23	(8) 6,3	373	D		
Common	Stock, par	value	\$.0001 per	share	01/05/	2017		S		853 ⁽¹⁾	D	\$133.65	(9) 5,	520	I	by spouse's trust	
Common	Stock, par	value	\$.0001 per	share	01/05/	2017		S		15 ⁽¹⁾	D	\$133.95	(2) 5,	505	I	by spouse	
Common	Stock, par	value	\$.0001 per	share	01/05/	2017		S		31(1)	D	\$135.69	(3) 5,4	474	I	by spouse	
Common	Stock, par	value	\$.0001 per	share	01/05/	2017		S		599(1)	D	\$137.56	(4) 4,	875	I	by spouse	
Common	Stock, par	value	\$.0001 per	share	01/05/	2017		S		421(1)	D	\$138.6 ⁽⁾	5) 4,4	454	I	by spouse	
Common	Stock, par	value	\$.0001 per	share	01/05/	2017		S		435(1)	D	\$139.49	(6) 4,	019	I	by spouse	
Common	Stock, par	value	\$.0001 per	share	01/05/	2017		S		117 ⁽¹⁾	D	\$140.59	(7) 3,9	902	I	by spouse	
Common	Stock, par	value	\$.0001 per	share	01/05/	2017		S		22(1)	D	\$141.22	(8) 3,	880	I	by spouse	
			7	Table II			ecurities Acquality						Owned				
1. Title of Derivative Security (Instr. 3)	L. Title of 2. 3. Transaction 3A. Deemed 4. Derivative Conversion Date Execution Date, Transaction or Exercise (Month/Day/Year) if any				4. Transacti Code (Ins	5. Number of Derivative	6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	Ownersh Form: Direct (D or Indire (I) (Instr.	Beneficial) Ownership ct (Instr. 4)		

			Table II - Deriv (e.g.,					ired, Disp , options,				Owned			
1. Title of Derivative Option to Purchase Common Stock	2. Conversion or Exercise Price of De\$26.64e Security	3. Transaction Date (Month/Day/Year) 01/05/2017	3A. Deemed Execution Date, if any (Month/Day/Year)	Code Transa Code (8)	etion	Deri Sec Acq or D of (I	u (D) er of vative urities uired (A) is7,932 ⁽¹⁾) (msu. and 5)	Expatis Exterd Expiration Do (Month/Day/) 08/12/2010	stabile and	Titletle and Amount of Commons UStock, in par value (1,0001 ar per share)	s _{7.932}	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or InDrect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Option to Purchase Common Stock	\$49.43	01/05/2017		М			5,572 ⁽¹⁾	08/11/2011 Date	05/11/2021 Expiration	Common Stock, par value \$.0001 per share	Ar _{0.0} nt or Number of	\$0	(Instr. 4)	D	
Option to Purchase Common Stock	\$85.75	01/05/2017		M	V	(A)	3,237 ⁽¹⁾	08/08/2012	05/08/2022	Stock, par value \$.0001 per share	3,237	\$0	0	D	
Option to Purchase Common Stock	\$96.35	01/05/2017		М			3,425 ⁽¹⁾	08/07/2013	05/07/2023	Common Stock, par value \$.0001 per share	3,425	\$0	0	D	

Explanation of Responses

- 1. This transaction is made pursuant to the terms of a sales plan designed to meet the requirements of Rule 10b5-1(c)(1) of the Securities Exchange Act.
- 2. This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$133.95 \$134.95. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- 3. This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$135.22 \$136.22. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- 4. This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$137.04 \$138.04. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- 5. This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$138.05 \$139.05. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- 6. This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$139.08 \$140.08. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- 7. This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$140.13 \$141.13. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- 8. This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$141.17 \$142.17. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- 9. This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$133.65 \$134.65. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.

Remarks:

/s/ Michael Greco Attorney-in-Fact for Alvin Parven 01/09/2017

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.